
AUPH
USDAurinia Pharmaceuticals Inc Ordinary Shares
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$8.050
High
$8.210
Low
$7.970
Volume
0.01M
Company Fundamentals
Market Cap
1.1B
Industry
Biotechnology
Country
Canada
Trading Stats
Avg Volume
1.40M
Exchange
NGM
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Apr 26, 2025AUPH: Aurinia Pharmaceuticals Inc Ordinary Shares - Checking the Pulse and What the Data Hints At
Stock Symbol: AUPH Generate Date: 2025-04-26 12:04:19
Alright, let's take a look at what's been going on with Aurinia Pharmaceuticals, ticker symbol AUPH. We've got some recent history, a bit of news, and even an AI's take on the next couple of days.
What's Been Happening? The News and the Price Tag
The main news item we have here is from back in February. Aurinia announced they'd be dropping their 2024 financial results on February 27th. Now, that news itself isn't good or bad – it's just letting everyone know when the report is coming out. But these financial reports are a big deal because they show how the company actually performed.
Looking at the stock price chart for the last few months, you can see that date, February 27th, stands out. The price took a pretty sharp dive right around then. Before that, the stock was trading mostly in the $7.80 to $8.30 range. After the earnings report came out, it dipped significantly, even touching the mid-$6 range briefly.
Since that earnings dip, the price has been quite volatile. It bounced back up into the $7s and $8s in March, even hitting a high around $8.85. Then it drifted lower again through late March and early April, finding a bottom around $7.00-$7.20. More recently, over the last couple of weeks in April, the stock has been climbing back up, getting back into the $8 range where it sits now. So, it's been a bit of a rollercoaster ride since that earnings announcement.
What the AI Sees Coming
We also have a peek at what an AI model predicts for the very near future. For today, it sees basically no change (0.00%). But for the next two days, it predicts small increases: 0.85% the first day and 1.91% the day after that. This suggests the AI thinks the recent upward nudge might continue just a little bit.
Putting It Together: What Does This Suggest?
Based on the recent price action – specifically the recovery from the early April lows – and the AI's forecast for slight near-term gains, the current situation might lean slightly positive for the very short term. The stock has shown it can recover after dips, and the AI seems to agree that the immediate trend is upward, albeit modestly.
Now, thinking about potential moves:
- If you're considering getting in: The stock is currently trading around the $8 mark. The recommendation data points to a support level near $8.05, which is right in this neighborhood. If you're comfortable with the volatility this stock has shown, this area could be a point to watch for a potential entry, aligning with the recent bounce and the AI's slight positive outlook.
- If you're already holding or thinking about managing risk: The recommendation data suggests a stop-loss around $7.27. This level makes sense because it's below the recent lows we saw in early April. If the price were to fall below there, it could signal that the recent recovery is failing. For taking profits, the AI only predicts small near-term gains. The recommendation data mentions a take-profit at $8.24, which is very close to the current price and the AI's predicted movement. Longer-term analyst targets are higher (around $9.83), but that's a different timeframe than the immediate AI prediction.
Keep in mind, this stock has a history of big swings, especially around company news like earnings reports. While the AI sees a small bump ahead, the overall picture includes that sharp drop we saw in February.
A Little About Aurinia
Just to add some context, Aurinia is a biotechnology company. They focus on developing treatments for autoimmune diseases, like lupus nephritis. Biotech stocks can often be quite sensitive to news about their drug trials, regulatory approvals, and sales performance. They can also have high valuations relative to their earnings (the recommendation data flagged a high P/E ratio), which can sometimes add to their volatility.
Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are inherently risky, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.
Related News
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company) today announced that it will release 2024 fourth quarter and full year financial and operational results before markets open on February 27,
AI PredictionBeta
AI Recommendation
Updated at: Apr 28, 2025, 06:50 AM
68.4% Confidence
Risk & Trading
Entry Point
$8.16
Take Profit
$8.69
Stop Loss
$7.37
Key Factors
Related Stocks

BEPH
Brookfield BRP Holdings (Canada) Inc. 4.625% Perpetual Subordinated Notes

CRSP
CRISPR Therapeutics AG Common Shares

MTEX
Mannatech Incorporated

BLFS
BioLife Solutions Inc.

APGE
Apogee Therapeutics Inc.
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.